Fabry Disease

Type: Keyphrase
Name: Fabry Disease
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

Amicus Therapeutics Analyst Report; Solid Pipeline and Near-term Catalysts by BrokerBank Securities, Inc.

/PRNewswire/ -- Lysosomal storage disorders are a group of approximately 50 rare inherited metabolic disorders resulting from defects in lysosomal function.  These severe, chronic genetic diseases have unmet medical needs, and include Fabry disease, Gaucher ... [Published CBS Detroit - Jul 07 2014]
First reported Jul 05 2014 - Updated Jul 05 2014 - 1 reports

Key Stocks With Insiders Buying This Week

In what was a historic week for the stock markets, with all the big indexes hitting all-time highs, that didn’t stop insiders from stepping up to the plate to purchase more stock. For investors, aggressive insider buying at the top range of a secular ... [Published 24/7 Wall St - Jul 05 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Up 20%: Time to Buy Amicus Therapeutics, Inc?

By | More ArticlesIn biotech, when you hear that a drug's peak sales estimates hover around $200 million, usually you shrug. But for a stock like Amicus Therapeutics (NASDAQ: FOLD Amicus announced yesterday that it would be reporting data from its phase ... [Published Motley Fool - Jul 01 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Amicus Therapeutics Surging On Phase 3 Plan Announcement

Amicus Therapeutics ( FOLD ) provided a detailed statistical analysis plan including updates on the company’s second Phase 3 study of its experimental drug, migalastat. The new study, titled Study 012, will further test migalastat as a monotherapy for ... [Published Bidness Etc - Jul 01 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese ...

In Taiwan, DNA-based newborn screening showed a surprisingly high incidence of a cardiac Fabry mutation (IVS4 + 919G A). The prevalence of this mutation is too high to be believed that it is a real pathogenic mutation.The purpose of this study is to identify ... [Published 7thSpace - Jul 01 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

Sector Update: Healthcare Stocks Losses Accelerate...

PFE -0.02%ABT +0.76%MRK +0.40%AMGN -0.26%Healthcare stocks slightly lower today were with the NYSE Healthcare Sector Index slipping about 0.3% and shares of healthcare companies in the S&P 500 also down about 0.5% as a group.In company news, Amicus Therapeutics ... [Published Nasdaq - Jun 30 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

Amicus Therapeutics Provides Updates and Final Analysis Plan for Phase 3 Fabry Monotherapy Study 012

Last Patient Completes 18-Month Primary Treatment Period - Top-Line Data on Track to Report in 3Q1496% of Patients with Amenable Mutations Elected to Continue in 12-Month Treatment ExtensionStatistical Analysis Plan FinalizedCRANBURY, N.J., June 30, 2014 ... [Published CW Atlanta - Jun 30 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

Support group helps sufferers with rare disease

Twenty years ago, The Weekly published an article about Fabry Disease - a rare and little known condition that causes its sufferers intense pain, and drastically reduces life expectancy. That article brought together Fabry sufferers from all over Australia, ... [Published Australian Women's Weekly - Jun 27 2014]
First reported Jun 26 2014 - Updated Jun 26 2014 - 1 reports

High-Risk Female Groups Screened for Fabry Disease

Although measurement of lysosomal α-galactosidase A (α-GAL) in women is not accurate for the diagnosis of Fabry disease (FD), determining the range of the enzyme activity presented by heterozygous females could become a valuable tool for minimizing the ... [Published Lab Medica - Jun 26 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 2 reports

Research and Markets: Global Fabry Disease Pipeline Report 2014-2017

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xs3qs6/fabry_disease) has announced the addition of the "Fabry Disease Pipeline Highlights - 2014 Update" report to their offering. The latest report Fabry Disease ... [Published Business Wire Health News - Jun 23 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 1 reports

Positive Preclinical Performance of greenovation`s Lead Candidate moss-Gal

: greenovation Biotech GmbH and Baylor Research Institute today announced positive preclinical results of greenovation’s plant-made version of human Alpha-Galactosidase (Gal) for use as enzyme-replacement-therapy (ERT) in patients suffering from Fabry ... [Published American Pharmaceutical Outsourcing - Jun 23 2014]
First reported Jun 13 2014 - Updated Jun 13 2014 - 1 reports

Findings from G. Pasqualim and Co-Researchers Advance Knowledge in Fabry Disease

(NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- A new study on X-Linked Genetic Diseases and Conditions is now available. According to news reporting originating from Porto Alegre, Brazil, by NewsRx correspondents, research stated, ... [Published NewsRX - Jun 13 2014]

Quotes

Amid pressure from shareholders, Shire confirmed that talks had taken place in New York but were at an early stage. In a press release Shire said: "There can be no certainty that any firm offer will be made nor as to the terms on which any firm offer might be made." It "strongly advised" shareholders not to take any action in relation to AbbVie's proposal
...for surgery, now have a new option," said Deepak Vivek, MD, interventional cardiologist and director, Orlando Health Heart Institute Valve Center. "Patients no longer have to live with severe chest pain, shortness of breath, fatigue and other symptoms of aortic stenosis, or limited treatment options that may not provide lasting results. Patients no longer have to live without hope for improvement. We are excited to bring advanced technology to improve outcomes for our patients."
"We rate AMICUS THERAPEUTICS INC (FOLD) a SELL. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity."
"Hopefully, migalastat will become an important new medicine for the treatment of Fabry disease, where so much unmet need remains" CEO John Crowley said in prepared remarks

More Content

All (49) | News (44) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Shire confirms talks with US drug firm AbbVie o... [Published Guardian.co.uk - Jul 11 2014]
14 Insanely Important Biotech/Drug Trading Cata... [Published TheStreet.com - Jul 10 2014]
14 Insanely Important Biotech/Drug Trading Cata... [Published The Street Latest - Jul 10 2014]
Doctors offer new minimally invasive system to ... [Published News-Medical.Net - Jul 09 2014]
Scientists discover new compounds that could al... [Published News-Medical.Net - Jul 08 2014]
Amicus Therapeutics Analyst Report; Solid Pipel... [Published CBS Detroit - Jul 07 2014]
Amicus Therapeutics Analyst Report; Solid Pipel... [Published Financial Services - Jul 07 2014]
Key Stocks With Insiders Buying This Week [Published 24/7 Wall St - Jul 05 2014]
Multiple Insiders of Amicus Therapeutics, Inc. ... [Published TradingCharts.com - Jul 02 2014]
Up 20%: Time to Buy Amicus Therapeutics, Inc? [Published Motley Fool - Jul 01 2014]
Amicus Up on Migalastat Study Update [Published Yahoo! Finance - Jul 01 2014]
Why Amicus Therapeutics (FOLD) Stock Continues ... [Published TheStreet.com - Jul 01 2014]
Why Amicus Therapeutics (FOLD) Stock Continues ... [Published The Street Latest - Jul 01 2014]
Janney Capital Upgrades Amicus Therapeutics, In... [Published Value Walk - Jul 01 2014]
Amicus Therapeutics Surging On Phase 3 Plan Ann... [Published Bidness Etc - Jul 01 2014]
Endomyocardial biopsies in patients with left v... [Published 7thSpace - Jul 01 2014]
Healthcare Review: GW Pharmaceuticals, Dicerna ... [Published BioMedReports - Jun 30 2014]
Sector Update: Healthcare Stocks Losses Acceler... [Published Nasdaq - Jun 30 2014]
Amicus Therapeutics Provides Updates and Final ... [Published CW Atlanta - Jun 30 2014]
Government funding only hope for patients with ... [Published DNA India - Jun 28 2014]
Support group helps sufferers with rare disease [Published Australian Women's Weekly - Jun 27 2014]
Protalix Announces New Data on ELELYSO(TM) (tal... [Published Franklin Credit Management Corporation - Jun 27 2014]
High-Risk Female Groups Screened for Fabry Disease [Published Lab Medica - Jun 26 2014]
Research and Markets: Global Fabry Disease Pipe... [Published Business Wire Health News - Jun 23 2014]
Positive Preclinical Performance of greenovatio... [Published American Pharmaceutical Outsourcing - Jun 23 2014]
Global Fabry Disease Pipeline Report 2014-2017 [Published Individual.com - Jun 23 2014]
Shire Sees ‘Significant’ Shareholder Value as A... [Published Washington Post - Jun 23 2014]
Here's Why AbbVie Wants to Cozy Up With Shire [Published Motley Fool Discussion Boards - Jun 23 2014]
Drugs firm Shire stands up to £27bn takeover bi... [Published Mail Online UK - Jun 22 2014]
Drugs firm Shire stands up to £27bn takeover bi... [Published This Is Money - Jun 22 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Research and Markets: Global Fabry Disease Pipe... [Published Business Wire Health News - Jun 23 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xs3qs6/fabry_disease) has announced the addition of the "Fabry Disease Pipeline Highlights - 2014 Update" report to their offering. The latest report Fabry Disease ...
Research and Markets: Fabry Disease - Pipeline ... [Published Business Wire Health News - Jun 10 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/fhx488/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information ...
Orphan designation: 1-Deoxygalactonojirimycin h... [Published Orphan designations - May 08 2014]
[tt] [GRG] Pompe's Disease [Published TranshumanTech - Jan 27 2014]
To Members and Friends of the Los Angeles Gerontology Research Group:         Pompe's Disease... -- Steve Coles "Agonizing Choices for Lives Saved by Miracle Drugs" by Geeta AnandSeven months ago, Megan Crowley made a gutsy decision: to undergo ...
1

Press Releases

sort by: Date | Relevance
Amicus Therapeutics Analyst Report; Solid Pipel... [Published Financial Services - Jul 07 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.